Wednesday, 18 Jul 2018

You are here

Advantages of Intravenous Pulse Cyclophosphamide in ANCA-associated Vasculitis

Researchers from the Nottingham University Hospitals have analyzed the efficacy and safety of  oral (PO) and intravenous (IV)  cyclophosphamide (CTX) in ANCA-associated vasculitis (AAV) patients and demonstrated a trend for fewer relapses, better 1 year survival and less toxicity with IV CTX.

We aimed to compare risk of death, relapse, neutropenia and infection requiring hospital admission between unselected ANCA-associated vasculitis (AAV) patients according to whether cyclophosphamide induction was by daily oral (PO) or pulse intravenous (IV) route.

They studied 57 newly diagnosed AAV patients treated with PO or IV cyclophosphamide from 3/07 to 6/13 and compared death, relapse, neutropenia and hospitalized infections, after adjusting for age, renal function and other significant confounders.

One-year survival was greater with IV CTX (98.2% vs 86%) compared to PO (HR  PO vs IV = 1.8; 95% CI 0.3–10.6, P = 0.54).

One-year relapse-free survival was higher w/ IV CTX (87.3% vs 80.7% (HR 3.8; 95% CI 0.2–846, P = 0.37).

Toxicities were more likely with PO CTX (compared to IV) in the first 12 months.

  • neutropenia (16% PO and 0 IV) (P = 0.003).
  • hospitalized infections (28% PO  vs 16% IV) (OR 2.2; 0.6–8.6, P = 0.23).
  • there was a trend towards more deaths and admissions with PO cyclophosphamide.

Overall oral administration of CTX induces greater marrow toxicity and more infections.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Hydroxychloroquine Being Over-Dosed with New Guidelines?

Hydroxychloroquine retinopathy prevention guidelines have revised from ideal body weight-based dosing to actual body weight-based dosing; the question remains whether these have been adopted in clinical practice. A database of nearly 21,000 new HCQ users from a UK general population database studied HCQ dosing and use between 2007 and 2016. Specifically they examined whether users were subjected to excess HCQ dosing per ophthalmology guidelines (defined by exceeding 6.5 mg/kg of IBW and 5.0 mg/kg of ABW).

NSAID Use Around Conception Increases Miscarriage Risk

A study from the American Journal of Obstetrics & Gynecology analyzed pregnant women from the Kaiser Permanente healthcare system and compared newly pregnant women who took non-steroidal anti-inflammatory drugs or acetaminophen or neither showed that using NSAIDs around conception carried a more than four-fold higher risk of early miscarriage. (Citation source: http://bit.ly/2tqNWN6)

Could Measuring Drug Levels with TNF Treatment Hurt Your Patients?

Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).

There have been GI trials with T2T with drug levels but they are not always suggesting that the strategy is superior to usual care. Also, this is really not a common practice in rheumatology.

Methotrexate Update

I was delighted to see that investigators presenting work at EULAR 2018 haven’t lost interest in our old friend methotrexate, with a number of abstracts examining issues of safety, dose and route of administration.

Low incidence of methotrexate induced liver abnormalities

Cancer Therapies Inducing Immune-Related Adverse Events (irAEs)

Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.

While being quite effective in oncology, these checkpoint inhibitors have led to the emergence of a quite unique spectrum of rheumatologic conditions presented under the umbrella of immune-related adverse events (irAEs).